Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer Treatment

October 27, 2015
Kimberly L. Blackwell, MD

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab. She says the drug was initially tested in both phase I and II trials, though the trials are being repeated to test margetuximab’s effectiveness on HER2-positive breast cancer.

Blackwell also says that if approved, margetuximab could benefit patients with HER2 over-expression that are not eligible for trastuzumab.